Protalix BioTherapeutics, Inc. (PLX) Financials
PLX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 89.8 million | 60.0 million |
2023-12-31 | 84.4 million | 50.9 million |
2023-09-30 | 87.6 million | 49.3 million |
2023-06-30 | 88.4 million | 49.4 million |
PLX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | 3.6 million | 981000 |
2023-12-31 | 3.3 million | 1.4 million |
2023-09-30 | -7.3 million | 1.1 million |
2023-06-30 | 4.8 million | 438000 |
PLX Net Income
No data available :(
PLX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 48.5 million | - | 6.0 million |
2023-12-31 | 44.6 million | - | 6.0 million |
2023-09-30 | 41.0 million | - | 5.8 million |
2023-06-30 | 48.2 million | 20.1 million | 5.8 million |
PLX Shares Outstanding
PLX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 598000 | 2.9 million | -562000 | 3.7 million |
2023-12-31 | 250000 | 3.1 million | 19.5 million | 10.1 million |
2023-09-30 | 447000 | 3.7 million | -6.5 million | 10.2 million |
2023-06-30 | 204000 | 4.5 million | -11.0 million | 15.1 million |
PLX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 3.7 million | 2.6 million |
2023-12-31 | 10.5 million | 8.9 million |
2023-09-30 | 10.3 million | 4.9 million |
2023-06-30 | 35.1 million | 6.1 million |
PLX
Price: $1.14
52 week price:
Earnings Per Share: 0.09 USD
P/E Ratio: 16.33
Exchange: ASE
Sector: Healthcare
Industry: Biotechnology
Volume: 637200
Market Capitalization: 82.8 million